• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

immatics biotechnologies

edit

immatics is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product can50 didates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 – and thus less than three years after the conclusion of the first round of funding totaling €14 million – the company successfully concluded an international clinical study on its product candidate IMA901 for combating renal cancer. Further product candidates, also consisting of peptide-based immuno55 therapeutic substances for cancer therapy, are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline.

Milestones

edit

• 
  immatics biotechnologies received $70.8M (€54M) in Series C funding. (9/21/10)
  Posted 9/21/10 at 6:36am via immatics.com
• 
  immatics biotechnologies received $7.5M in Series B funding. (4/15/05)
  Posted 7/5/10 at 3:14am
• 
  immatics biotechnologies received $52M (€40M) in Series B funding. (2/8/07)
  Posted 3/10/10 at 11:16pm via tornado-insider.com

Videos

Screenshots

edit

Above: immatics biotechnologies
Uploaded: 3/11/10

Sources

1. Cap Funding Report [edit]
2. immatics receives €40 million in second round of funding (tornado-insider.com) [edit]
3. immatics raises €54 million to advance its late stage clinical therapeutic cancer vaccine portfolio (immatics.com) [edit]